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Abstract 
Differences of sex development (DSD) are defined as conditions with discrepancies between 
chromosomal, gonadal and phenotypic sex. In congenital hypogonadotropic hypogonadism (CHH), a 
lack of gonadotropin activity results primarily in the absence of pubertal development with prenatal 
sex development being (almost) unaffected in most patients. To expedite progress in the care of 
people affected by DSD and CHH, the European Union has funded a number of scientific networks. 
Two Actions of the Cooperation of Science and Technology (COST) programmes — DSDnet (BM1303) 
and GnRHnetwork (BM1105) — provided the framework for ground-breaking research and allowed 
the development of position papers on diagnostic procedures and special laboratory analyses, as well 
as clinical management. Both Actions developed educational programmes to increase expertise and 
promote interest in this area of science and medicine. In this Perspectives, we discuss the success of 
the COST Actions DSDnet and GnRHnetwork, and the European Reference Network for Rare Endocrine 
Conditions (Endo–ERN) and provide recommendations for future research.  
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Introduction 
The Cooperation of Science and Technology (COST) programme aims to increase the networking 
possibilities for scientists and to fund activities through the European scientific funding 
programme Horizon 2020. COST Actions, which are networks dedicated to scientific collaboration 
and complement national research funds, provide the opportunity to hold workshops and 
meetings and offer support for early stage researchers (PhD students or post-doctoral fellows 
within 8 years of their PhD) through short-term scientific missions and training schools. COST 
Actions are joined by countries within Europe, but also include near neighbouring countries and 
international partners. Interestingly, COST Actions are not closed projects, but are open to all 
opinion leaders from the participating countries.  
COST Actions provide excellent tools for scientists involved in research on rare diseases in 
medicine, because here, expertise is often scattered, and effective networking is necessary for 
increasing knowledge and achieving appropriate attention. From 2012 to 2017, COST funded two 
European concerted Actions for the systematic elucidation of differences of sex development 
(DSD) and for congenital hypogonadotropic hypogonadism (CHH) resulting from gonadotropin-
releasing hormone (GnRH) deficiency. CHH is frequently associated with anosmia (Kallmann 
syndrome) and has variable clinical features. Both Actions had similar structured approaches 
concerning clinical care, genetic testing and scientific research, as well as education and training. 
The development of sex and gender, and the elucidation of variant physiology, are some of the 
most complex topics in biology and medicine, as well as in society. The main objective of the COST 
Actions was to promote research into sex development and maturation, spanning the whole 
patient journey from diagnostic molecular studies to treatment, in order to improve the structured 
care and health of people with DSD or CHH. The Actions were designed to aid understanding of 
the underlying clinical heterogeneity of DSD or CHH, as well as reveal the pathophysiological 
commonalities between the different conditions at the molecular level. Additionally, we wanted 
the Actions to benefit the scientific investigation of rare diseases in the international community 
and to promote the formation of a European Reference Network for better visibility of patient 
care. 
DSDnet was built on the framework of pre-existing collaborations that took shape following the 
Chicago consensus in 20051 and included the DSD Working Group of the European Society for 
Paediatric Endocrinology, EuroDSD (funded by 7th Framework Programme of the European Union), 
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and the international I-DSD and I-CAH registries. DSDnet was designed to promote collaboration 
with the project DSDLife, which was also funded within the 7th Framework Programme of the 
European Union. The GnRHnetwork began earlier, in April 2012, lasted until April 2016 and was 
characterized by interdisciplinary interaction of physicians and more basic scientists.  
Our knowledge on the prenatal sex development and pubertal maturation pathways has improved 
considerably in the past 20 years due to cutting-edge research on mammalian development and 
elucidation of underlying genetic mechanisms29,30. In parallel, descriptive clinical outcome studies 
have provided some insight into the long-term outcome of affected people31,32,33. However, the 
results of these studies are mostly inconclusive due to the small sample sizes and broad 
heterogeneity of participants as well as differences in applied methodology and measures.  
To provide better care for its citizens with rare and complex health issues, the EU has established 
the European Reference Networks (ERNs) for rare conditions. In 2017, 24 ERNs were founded, 
encompassing the majority of the >8,000 rare conditions known today. The ERN for Rare 
Endocrine Conditions (Endo–ERN) is divided into eight Main Thematic Groups (MTGs), which cover 
all rare endocrine disorders over the lifespan. The aim of Endo–ERN is to diagnose these conditions 
promptly and effectively, whilst minimizing the inequities that exist for the care of affected people 
across the EU. Within Endo–ERN, the MTG ‘Sex Development and Maturation’ was established, 
which stems from previous participants of the COST Actions DSDnet and GnRHnetwork and whose 
members will build its future aims for patient care on the achieved results.  
 
In this Perspectives article, we describe the achievements of these two related COST Actions and 
highlight the gaps in research that were identified. Future investigations should take these 
considerations into account  
[H1] Achievements of the COST Actions 
[H2] Clinical assessment 
The clinical findings of conditions that effect sex development and maturation can be highly 
variable and sometimes clinically undetectable34. This clinical observation holds true for conditions 
such as complete gonadal dysgenesis (where the external phenotype is female, even if the 
karyotype is 46,XY) and in patients who are 46,XX and have CHH (who are unequivocally female at 
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birth). All DSD can have associated features, with complex syndromes affecting almost all organ 
systems, but mainly the kidneys, the heart, the peripheral and central nervous systems2. 
Therefore, any clinical investigation needs to take further developmental anomalies into account.  
The clinical assessment of a patient needs to be age-dependent and include an extensive whole-
body examination, including the genital status. In the young child, the inspection of the genitalia 
might reveal micropenis (<2 SD of normative value) and cryptorchidism. Only in DSD conditions, 
hypospadias or further genital ambiguity will be found. At the time of puberty, in both DSD and 
CHH delay of pubertal development might be a hallmark. Both of the COST Actions published 
recommendations on standardized clinical assessment3-5. For DSD, the external masculinization 
score6, which was originally designed to describe genitalia in undervirilized male infants, was 
modified into a more widely applicable ’external genitalia score’ (EGS) to cover the whole 
spectrum of genital appearance in both male and female infants. The tool that resulted following 
the modifications will become available to be incorporated into online platforms such as the I-DSD 
for collection of standardized phenotypic data by the end of 2019. 
A template for longitudinal follow-up has been created in conjunction with the I-DSD registry. 
Within this longitudinal follow-up tool some questions on overall health, endocrine status, genital 
anatomy and function, need for psychosocial support and gender congruence have to be 
considered equally important if we want to improve the quality of life of all patients with a DSD 
condition. A simple screen such as this might be sufficient for use in the routine clinical setting and 
could be followed up with more detailed assessment if indicated. 
For clinical and research purposes, we considered it crucial to standardize a minimal set of time 
points, corresponding to important developmental milestones, at which relevant clinical data should 
be collected, although most patients will need medical evaluations more often than these minimums. 
Consensus was reached on the following time points: assessment at diagnosis and at ages 4 years and 
8 years allows for documentation of psychological developmental milestones and gender 
development, presence of associated symptoms and growth patterns, and ensures the provision of 
timely and adequate information to the child and their parents. At the start and at the termination of 
puberty, and at the transition to adult care, documenting the outcome of pubertal development and 
the physical and mental status was considered paramount. Various age intervals were identified in 
adulthood and each has specific requirements. At ages 18-25 years independence is gained and new 
intimate relationships are formed. At ages 25-40 years issues around fertility and forming a family 
might dominate discussions with patients. By contrast, at age intervals 40-60 years and 60-80 years, 
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long-term effects of treatment or (lack of) hormonal treatment and co-morbidities might become 
apparent (unpublished data and REF 5)  
Several experts of the GnRHnetwork COST Action conducted or reviewed multicentre trials that 
highlight the need for improved management of affected patients and the importance of a 
structured and life-long clinical assessment. In particular, Andrew Dwyer and colleagues 
conducted the first and only randomized clinical trial on the induction of puberty, testicular growth 
and fertility in treatment naive young adults with GnRH deficiency7. They evaluated the fertility 
outcomes by sperm count and surrogate markers during a 24-month pulsatile GnRH 
administration versus 4-month of recombinant human FSH (rhFSH) pretreatment followed by 24 
months of GnRH therapy. They demonstrated the superiority of rhFSH pre-treatment on both 
surrogate markers (including testicular volume) and sperm count. A subsequent review of the 
GnRH-network experts confirmed the superiority of rhFSH pretreatment before the combined 
gonadotropin or pulsatile GnRH administration for the induction of pubertal development and 
testicular growth in patients with severe GnRH deficiency8. In addition, the GnRH COST action 
evaluated the psychosexual development of 101 men with CHH9. The study revealed that male 
patients with CHH frequently experience psychosexual problems that hamper intimate 
relationships and the initiation of sexual activity. These persistent effects cause considerable 
distress and are not ameliorated by long-term treatment. Therefore, psychosexual assessment 
followed by appropriate psychological support and treatment is warranted in these patients. 
 
[H2] Genetics 
Both Actions, DSDnet and GnRHnetwork, stratified a diagnostic approach to elucidate the 
underlying genetic anomaly and published position and consensus papers on this topic3,10. In 
people with DSD, the determination of a karyotype is still seen as an initial mandatory step, as 
numerical or structural chromosomal abnormalities account for a considerable subset of DSD 
conditions. However, many patients with DSD or CHH might have an unaffected chromosomal 
complement, and so detailed studies for molecular genetic conditions are needed.  
Both Actions favoured collaboration between basic scientists and clinicians to understand the 
molecular aetiology and develop collaborative bioinformatics tools to rapidly aid the identification 
of novel genetic causes. Collaborations within GnRHnetwork led to the discovery of several novel 
candidate genes underlying CHH11-15. The collaborative efforts in DSDnet led to the identification 
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of variants in a new gene associated with 46,XY DSD16 and mutations in a nuclear factor, NR2F2, 
which cause a novel syndromic form of 46,XX DSD17. We predict that it is highly likely that other 
new genes causing DSD will be identified through the DSDnet and Endo–ERN collaborative 
network in the near future. 
In 2015, the first European Consensus Statement on CHH was published. The consensus document 
covers aspects related to the pathogenesis, diagnosis and treatment of this rare condition3. This 
document is the result of the interaction between the members of the clinical and genetic working 
groups of the GnRHnetwork. In particular, the experts documented the existence of particular 
phenotype–genotype correlations (for example, CHH and hearing loss are particularly frequent 
among patients with SOX10, IL17RD or CHD7 gene defects) and provided recommendations for 
improved treatment of patients with CHH examining early, but also later, outcomes including 
future fertility. 
Despite these important advances, the majority of patients, particularly those with 46,XY 
conditions that effect sex development and maturation (excluding primary errors of the endocrine 
system) do not have a molecular diagnosis. The accurate interpretation of high-throughput 
sequencing datasets is challenging in the clinical setting. The challenges arise in part due to 
emerging evidence that these conditions might be caused by variants in many different genes, and 
the prevalence of variants in a single gene could be very low35. To build robust evidence to support 
causality, sharing genomic data between research groups and developing informative animal and 
cellular models are required.  
 
To improve the way in which we share genomic data, DSDnet established a secure platform for 
sharing data between research groups, called ‘SDgeneMatch’36. A 'match' occurs when two users 
of the system are found with a variant in the same gene. Matches are reported to the two 
researchers that supplied the relevant gene identifier. Reporting of matches will be done behind 
the password-protected environment of SDgeneMatch, ensuring only the users that originally 
uploaded the match will be able to learn the gene name of the match. Although other gene 
matching systems do exist, SDgeneMatch is currently specific for DSD, and the DSD research 
community will be actively encouraged to submit data into the system. Matching data in this way 
can accelerate gene and/or variant discovery in the field and encourage collaboration with groups 
working on animal and/or cellular model systems in order to provide evidence of causality, as well 
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as explore the molecular pathways that are involved. In addition, data matching will lead to a more 
accurate molecular diagnosis for DSD. 
< BOX 1 > 
[H2] Endocrine assessment 
Rare endocrine conditions, such as DSD and CHH, are often genetically determined and feature 
hormonal imbalances as the result of divergent endocrine pathways. However, in childhood and 
puberty, endocrine abnormalities can be difficult to detect and tend to be highly variable 
depending on age and developmental stage of the affected person34. 
Therefore, the COST Actions first aimed to identify appropriate laboratory determinations that are 
useful in the complex differential diagnostics of DSD and CHH. Second, the COST Actions aimed to 
develop guidelines for the usefulness of specific laboratory analyses and testing conditions. These 
guidelines were directed toward the implementation of clinical standards for diagnosis and 
appropriate treatment of DSD and CHH to achieve the best outcomes for patients, no matter 
where patients are investigated or managed3,18-20. 
In a position paper by Alexandra Kulle and colleagues, all forms of DSD were summarized and, for 
each condition, the required hormonal work-up and suitable analytical techniques were described 
18. The main recommendations were: support the appropriate use of both immunoassay-based 
and mass spectrometry-based methods for the diagnosis and monitoring of DSD; use of both 
serum and urine is established and appropriate matrices used for analysis of steroids; and 
laboratories should aim to participate in activities of peer comparison18.  
The next step for the harmonization of laboratory assessments relates to the important plasma 
and/or serum analyte 17-hydroxyprogesterone, which is a key marker in the diagnosis of 
congenital adrenal hyperplasia21. Hereto, we conducted, in collaboration with colleagues in China, 
Singapore and Australia, a worldwide survey on mass spectrometric determinations of this 
analyte. This collaboration resulted in a publication21 that pointed out that although mass 
spectrometry-based methods are similar in many facets, they are highly disparate, leading to 
heterogeneous reference values over the whole lifespan. Consecutively, five recommendations 
have been developed to support the continued improvement of analysis of plasma or serum 17-
hydroxyprogesterone by mass spectrometry21. 
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[H2] Education and training 
Both COST Actions used the specific tools of the COST programme to provide training and 
education to early stage researchers. Specifically, they developed the Action websites DSDNet and 
CHUV and coordinated and integrated the activities of the other Working Groups. Some of the 
scientific efforts were translated into public dissemination through a series of articles (full list at 
DSDNet and CHUV meetings (6 working group meetings and/or workshops for DSDnet, the last 
one in combination with GNRHnetwork) and position papers3,5,10,18,22. 
The COST Actions used part of their funds to provide training for eligible young scientists and 
organized three training schools. The three training schools were set up to provide 
multidisciplinary training to young professionals (trainees) and encourage ongoing activity in the 
field of DSD and CHH. These interactive meetings, each of which included ~30 trainees and 10 
trainers, have been designed to cover important topics relevant to science and clinical work. The 
key long-term aim of each training school was to encourage the trainees to be involved in and to 
improve the national and international networking capabilities of interdisciplinary research for 
breakthrough science. To achieve the key long-term aim within DSDnet, for example, trainees 
were encouraged to participate in the I-DSD registry, apply for grant and fellowship applications 
in the field of DSD and become active members of the European Reference Network for Rare 
Endocrine Conditions (Endo–ERN).  
 
A report that analyzed, through specific surveys, the success and subsequent outcome of the 
training schools for the trainees was published in 201923. Briefly, the high rate of positive 
responses from trainees demonstrates the success of the training school model that the DSDnet 
has adopted, and shows that the majority of the participating trainees are still active in the DSD 
field. These positive results justify the continuation of this form of postgraduate multidisciplinary 
training. 
Another educational tool is the organization of the short-term scientific missions (STSM). The 
STSMs were aimed at supporting individual mobility in order to share knowledge and technology 
that might not be available in the home institution, strengthening the existing networks in the 
field and fostering collaborations by allowing scientists to visit an institution or laboratory in 
another participating COST country. There were three grant periods throughout the duration of 
the COST Actions. The overall comparison between the number of STSMs during COST Action 
DSDnet (n = 10 between 2015 and 2017; 3.33 per year) and COST Action GnRHnetwork (n = 23 
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between 2013 and 2016; 5.75 per year) of our partners in the European Reference Network for 
Rare Endocrine Conditions (Endo–ERN) demonstrates some differences in missions between the 
two actions. One possible explanation could be the increased participation of basic scientists in 
GnRHnetwork, who are willing and able to perform an STSM in another laboratory site. By 
contrast, the participation of clinical scientists in such exchanges could be hampered by their 
clinical duties. 
[H2] Improving patient care 
We need to promote and optimize patient management and care for the complex conditions 
involved in sex development and maturation. DSDnet intended to understand the current practice 
and research priorities amongst professionals and patients. These objectives were primarily 
achieved through a series of web-based surveys that targeted paediatric endocrinologists, 
providers of psychosocial support and paediatric surgeons and urologists24,25.  
  
The survey that was aimed at paediatric endocrinologists revealed that 40% of the DSD centres 
had a multidisciplinary team available at initial presentation24. Half of the centres reported that 
they share their data in a multicentre registry. In addition, the survey revealed that local access to 
specialist biochemical and genetic tests influenced the diagnostic process, and that detailed 
molecular genetic testing was becoming routine. Approximately one third of regions surveyed had 
seen the development of clinical networks. Expert centres were increasingly disseminating 
knowledge to non-expert centres through arranging local clinical meetings, case discussion and 
regional DSD clinics. Evidence of conferences and training days and e-learning tools was also 
reported. Survey participants suggested a number of research priorities, which highlights, among 
other requirements, the need for more studies that aim to understand and improve the quality of 
life.  
 
In this survey, paediatric endocrinologists were asked to rate their research priorities in order of 
importance24, see table 1 for a summary. Most frequently indicated topics were development of 
DSD-specific HRQoL measures and interventions that will improve quality of life, gender 
development and fundamental research on basic mechanisms underlying DSD and DSD-related 
disease 24. The survey among providers of psychosocial care investigated access to and modalities 
of psychosocial care, organization and practice25. The survey revealed that psychosocial care is 
predominantly provided to parents and focuses on coping and acceptance of the diagnosis and 
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the atypical genitalia, decisions on genital surgery, disclosure and education. Adult patients have 
less access to counselling than parents, children and adolescents25. Given that this age group in 
particular require support for coping with a range of DSD-related health and psychosexual 
issues37,38,39,40 , improving the accessibility of psychosocial counselling for adults should be 
prioritized. Sexuological counselling for men and women with DSD hardly received attention in 
the survey; however, there is a compelling need for development of sex therapies focused on 
sexual problems experienced by men and women with DSD. Providers of psychosocial care have a 
wide range of training backgrounds. This variety and the absence of an overarching professional 
body hinder professional development25. 
< BOX 2 > 
The assessment of patient needs was emphasized by both Actions, DSDnet and GnRHnetwork. A 
DSDnet face-to-face workshop that was held for 33 patients, their relatives and professionals 
included one or more patients and a health-care professional from the same centre from eight 
different European countries26. The focus of this workshop was to understand the needs and 
perceptions of those patients and parents who had recent experience of health care within the 
centres represented within DSDnet. In addition, there were five professionals who ran the 
breakout sessions and ten people who represented support groups. The background of the 
professionals included endocrinology, psychology, nursing, sociology and urology. Topics 
discussed included experiences around diagnosis, childhood and experiences of young people, 
experiences of transition to adult services, the I-DSD registry, future research areas, obtaining 
consent in practice and patient education and information resources. All attendees acknowledged 
the constructive nature of the workshop. The collaborative model of the workshop offered 
valuable ideas to improve clinical services, perform patient oriented research and optimize the 
development and use of registries25. The model that was used for these workshops can be 
extended in the future to engage in a separate setting with human rights and intersex advocacy 
organizations. 
GnRHnetwork included patients’ perspectives in their annual meetings27. The patients’ point of 
view formed an important component of these meetings, thus providing a novel opportunity for 
health-care professionals to identify particular gaps in patient care. In particular, the GnRH Cost 
Action conducted the first survey evaluating the unmet needs in 105 adult males with CHH27. The 
study was publicized online via a closed (private) CHH social media group (Facebook), CHH forum 
(chat room), a clinical trials registry and the COST Action website. The survey revealed that male 
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patients with CHH often have long gaps in care and still struggle with considerable psychosocial 
sequelae that are often unrecognized by the health-care community. A specific component within 
the GnRHnetwork’s web-page was created and currently represents a friendly and functional tool 
for researchers and physicians in the EU and patients involved in the area of CHH. Researchers and 
physicians are able to connect to other members of the consortium through this web page, in 
order to share their data and establish productive collaborations. In addition, educational 
materials co-created by expert clinicians and patients, which have been translated into different 
languages, were developed and included in the web page41. The addition of the educational 
material will help patients and their families to understand all forms of GnRH deficiency, find 
centres of excellence to optimize their treatment, learn how to prepare for a visit with their doctor 
and discover research centres where they can participate in studies. This additional resource also 
means that patients and their families can browse online resources and support groups and find 
answers to their questions. This process might serve as a roadmap for creating patient education 
materials for other rare diseases. 
< BOX 3 > 
[H1] Future research needs 
Future research priorities can be identified through the achievements of the international 
networks as they incorporated a broad variety of professionals with clinical and basic science 
backgrounds. In addition, the international networks also involved patients and patient advocates 
as important opinion leaders. 
Needs that can be addressed by the systematic and standardized data collection strategies 
proposed by the COST Actions include the development of treatment protocols that improve 
clinical outcomes and quality of life28. Furthermore, the collection and analysis of long-term post-
surgery data, the effect of living with atypical genitalia, gender well-being and overall health of 
individuals who have a DSD or CHH through the transition phase and at older ages need to be 
investigated. A major challenge that needs addressing is that all these data, which are often the 
result of medical management that took place several decades ago, need to be interpreted in the 
societal and medical context of today. Research priorities will have to be set in discussion with 
clinicians and patient advocates, who are currently involved as European Patient Advocacy Groups 
(EPAGs) in the Endo–ERN, acting as a partnership between patients, researchers and health-care 
COST Perspectives  Page 13 
 
providers. The common objective of research into this area is the improvement of clinical care and 
long-term outcomes. 
As increasing numbers of patients with rare, and presumably genetically determined complex 
conditions, undergo genomic sequencing42, there is increasing concern about the ability to 
robustly establish causality for novel therapeutic candidates. Thus, basic research is equally as 
important and complements clinical science, as it minimizes misidentification of condition-related 
genes and an erroneous interpretation that will have severe consequences for the patients and 
their families. Some forms of DSD and CHH are very rare and providing statistical evidence in 
favour of causality might not be possible, despite data sharing platforms.  
  
An important additional tool for the identification of novel therapeutic candidates consists of the 
study of mouse models. Variants in a human gene associated with sex development and 
maturation can be modelled in the mouse in a number of ways. First, a null (complete loss of 
function) allele can be generated rapidly using CRISPR–Cas9 genome editing technology — such a 
mouse variant immediately answers the question of whether the gene is required for normal sex 
development in a related mammal and conditional gene deletion approaches can also be 
performed43, 44.. Secondly, specific sequence variants (point variants, for example) can also be 
introduced by genome editing45. This facility is important if the human variant does not represent 
a loss-of-function allele. Thirdly, gain-of-function might also be modelled by over-expression 
transgenesis46. The power of mouse models lies in the ability of researchers to perform 
examination of gene function in a whole organismal context, in a mammalian model that shares 
many fundamental genetic pathways with humans. Mouse models also permit the study of the 
role of genetic background, which can have profound effects on penetrance and expressivity. 
The drawback to mouse models, however, is that they are not human. Differences between mouse 
and human reproductive biology are widespread. Another complementary tool for the analysis of 
novel gene variants consists of the use of cellular reprogramming technology. Here, candidate 
variants can be introduced into cell lines and/or induced pluripotent stem cells (iPSCs) and their 
effect on the reprogramming or derivation of somatic cells of either the testis or ovary can be 
assessed. Such approaches can be combined with genome editing techniques to permit the 
generation of cell lines in which rare variants are ‘corrected’ such that a common allele is now 
present, thereby acting as a powerful control. 
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The biology and genetics of a patient’s response to treatment, the influence of a patient’s genome 
on long-term outcomes and the potential development of comorbidities are poorly understood. 
In part, this lack of understanding reflects the need for us to further investigate the genetic 
aetiology of variant sex development and maturation in general, in addition to the absence of 
follow-up studies combined with deep phenotyping and harmonization of laboratory data. Thus, 
the collection of detailed and standardized phenotypic data over the longer term should be 
performed in parallel to the compilation of genetic data to improve our understanding of the wider 
health implications of existing and novel genetic variants in the field. Such studies will be made 
possible following the development of a European Registry for Rare Endocrine Conditions and by 
increasing the awareness and participation in existing registries28. 
The diagnostic pathway in patients with variant sex development and maturation requires close 
interlinking between the clinical, biochemical and genetic diagnostic work-up. The relevance of 
genetic testing for the differential diagnosis between CHH and constitutional delays of growth and 
puberty, a frequent para-physiological condition confounding the early recognition of patients 
with GnRH deficiency, was recently reported by a group of experts of the GnRH COST action47. 
However, currently, health-care systems across Europe differ greatly in structure and funding (see 
European Reference Networks on Rare Conditions (ERN) for examples). These disparities result in 
heterogeneous clinical and laboratory resources in the respective countries. In addition, and 
although highly desirable in such a complex field, interaction with research laboratories is often 
not possible, due to lack of access and funding, as well as ethical implications of data security 
measures. Consequently, diagnosis and management depend heavily on local or national 
pathways. With regards to reasonable hormonal determinations, highly qualified and specialized 
laboratories across European countries are required. This task is currently promoted by the ERN, 
which is due to be established in EU countries. Close interactions between patients and their 
families and health-care providers, as well as valid research, can improve medical care for people 
with conditions affecting sex development and maturation, and diminish the discomfort in society 
and the medical community towards gender variances21.  
< BOX 4 > 
[H1] Conclusion 
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The development of two COST Actions — DSDnet and GnRHnetwork — led to key advances in the 
field of sex development and maturation, thanks to the involvement of experts from different 
disciplines and affected individuals. However, there is a clear need to continue the momentum in 
this rapidly evolving field with studies following on from this large body of work. Such studies 
would fill the gaps that still hamper basic understanding of the physiological and 
pathophysiological events and their inclusion into optimal patient management. Furthermore, 
ongoing progress must be made in science to aid other public and political stakeholders in their 
decision-making regarding various aspects of dealing with diversity of sex in society and culture. 
These advancements might be possible through the development of Endo–ERN, which is a 
structure without time limits that harbors the clinical participants and stakeholders from the 
affected community within the political EU. Endo–ERN will make expert patient care visible and 
allow for clinical management progress. However, there are several issues that need to be 
addressed. First, the ERNs currently do not allow non-EU participants, because the ERNs have to 
adhere to the EU legal frameworks of health care. Second, one of the main purposes of the COST 
Actions, namely the networking of basic and clinical scientists, is restricted in ERNs because pure 
research institutions are not part of the ERNs at this time. Therefore, further possibilities that 
allow both clinical and translational science to be part of networking activities need to be sought. 
One possibility is the inclusion of ERNs and researchers into the European Joint Program Cofund, 
which was just positively reviewed and granted as a collaborative project in the European funding 
programme Horizon 2020, to promote research, education and training in rare diseases. 
Furthermore, connection to clinicians, translational and basic scientists outside of the European 
Union has to be sought and respective co-funding programmes for international collaborative 
research need to be developed. 
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GHRH Network: www.gnrhnetwork.eu 
I-DSD Registry: www.i-dsd.org 
I-CAH Registry: www.i-cah.org 
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DSDNet: www.dsdnet.eu 
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References 
1 Hughes, I. A. et al. Consensus statement on management of intersex disorders. Archives of 
diseases in childhood 91, 554-563, doi:10.1136/adc.2006.098319 (2006). 
2 Cox, K. et al. Novel associations in disorders of sex development: findings from the I-DSD 
Registry. The Journal of clinical endocrinology and metabolism 99, E348-355, 
doi:10.1210/jc.2013-2918 (2014). 
3 Boehm, U. et al. Expert consensus document: European Consensus Statement on congenital 
hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment. Nature reviews. 
Endocrinology 11, 547-564, doi:10.1038/nrendo.2015.112 (2015). 
4 Bonomi, M. et al. Characteristics of a nationwide cohort of patients presenting with isolated 
hypogonadotropic hypogonadism (IHH). European journal of endocrinology 178, 23-32, 
doi:10.1530/EJE-17-0065 (2018). 
5 Cools, M. et al. Caring for individuals with a difference of sex development (DSD): a 
Consensus Statement. Nature reviews. Endocrinology 14, 415-429, doi:10.1038/s41574-018-
0010-8 (2018). 
6 Ahmed, S. F., Khwaja, O. & Hughes, I. A. The role of a clinical score in the assessment of 
ambiguous genitalia. BJU Int 85, 120-124 (2000). 
7 Dwyer, A. A. et al. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-
induced fertility in patients with congenital hypogonadotropic hypogonadism. The Journal of 
clinical endocrinology and metabolism 98, E1790-1795, doi:10.1210/jc.2013-2518 (2013). 
8 Dwyer, A. A., Raivio, T. & Pitteloud, N. Gonadotrophin replacement for induction of fertility in 
hypogonadal men. Best practice & research. Clinical endocrinology & metabolism 29, 91-103, 
doi:10.1016/j.beem.2014.10.005 (2015). 
9 Dwyer, A. A., Quinton, R., Pitteloud, N. & Morin, D. Psychosexual development in men with 
congenital hypogonadotropic hypogonadism on long-term treatment: a mixed methods 
study. Sexual medicine 3, 32-41, doi:10.1002/sm2.50 (2015). 
10 Audi, L. et al. GENETICS IN ENDOCRINOLOGY: Approaches to molecular genetic diagnosis in 
the management of differences/disorders of sex development (DSD): position paper of EU 
COST Action BM 1303 "DSDnet". European journal of endocrinology, doi:10.1530/EJE-18-
0256 (2018). 
11 Cariboni, A. et al. Dysfunctional SEMA3E signaling underlies gonadotropin-releasing hormone 
neuron deficiency in Kallmann syndrome. The Journal of clinical investigation 125, 2413-
2428, doi:10.1172/JCI78448 (2015). 
12 Parkash, J. et al. Semaphorin7A regulates neuroglial plasticity in the adult hypothalamic 
median eminence. Nature communications 6, 6385, doi:10.1038/ncomms7385 (2015). 
13 Miraoui, H. et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in 
individuals with congenital hypogonadotropic hypogonadism. American journal of human 
genetics 92, 725-743, doi:10.1016/j.ajhg.2013.04.008 (2013). 
14 Xu, C. et al. KLB, encoding beta-Klotho, is mutated in patients with congenital 
hypogonadotropic hypogonadism. EMBO molecular medicine 9, 1379-1397, 
doi:10.15252/emmm.201607376 (2017). 
15 Bouilly, J. et al. DCC/NTN1 complex mutations in patients with congenital hypogonadotropic 
hypogonadism impair GnRH neuron development. Human molecular genetics 27, 359-372, 
doi:10.1093/hmg/ddx408 (2018). 
16 Harris, A. et al. ZNRF3 functions in mammalian sex determination by inhibiting canonical 
WNT signaling. Proceedings of the National Academy of Sciences of the United States of 
America 115, 5474-5479, doi:10.1073/pnas.1801223115 (2018). 
COST Perspectives  Page 19 
 
17 Bashamboo, A. et al. Loss of Function of the Nuclear Receptor NR2F2, Encoding COUP-TF2, 
Causes Testis Development and Cardiac Defects in 46,XX Children. American journal of 
human genetics 102, 487-493, doi:10.1016/j.ajhg.2018.01.021 (2018). 
18 Kulle, A. et al. Steroid hormone analysis in diagnosis and treatment of DSD: position paper of 
EU COST Action BM 1303 'DSDnet'. European journal of endocrinology 176, P1-P9, 
doi:10.1530/EJE-16-0953 (2017). 
19 Segal, T. Y., Mehta, A., Anazodo, A., Hindmarsh, P. C. & Dattani, M. T. Role of gonadotropin-
releasing hormone and human chorionic gonadotropin stimulation tests in differentiating 
patients with hypogonadotropic hypogonadism from those with constitutional delay of 
growth and puberty. The Journal of clinical endocrinology and metabolism 94, 780-785, 
doi:10.1210/jc.2008-0302 (2009). 
20 Trabado, S. et al. Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic 
hypogonadism/Kallmann syndrome and effects of different modalities of hormonal 
treatment: a single-center study of 281 patients. The Journal of clinical endocrinology and 
metabolism 99, E268-275, doi:10.1210/jc.2013-2288 (2014). 
21 Greaves, R. F. et al. Current state and recommendations for harmonization of serum/plasma 
17-hydroxyprogesterone mass spectrometry methods. Clinical chemistry and laboratory 
medicine 56, 1685-1697, doi:10.1515/cclm-2017-1039 (2018). 
22 Cools, M. et al. Response to the Council of Europe Human Rights Commissioner's Issue Paper 
on Human Rights and Intersex People. European urology 70, 407-409, 
doi:10.1016/j.eururo.2016.05.015 (2016). 
23 Bertalan, R. et al. Evaluation of DSD training schools organized by cost action BM1303 
"DSDnet". Orphanet J Rare Dis 13, 227, doi:10.1186/s13023-018-0967-3 (2018). 
24 Kyriakou, A. et al. Current models of care for disorders of sex development - results from an 
International survey of specialist centres. Orphanet J Rare Dis 11, 155, doi:10.1186/s13023-
016-0534-8 (2016). 
25 Dessens, A. et al. Understanding the needs of professionals who provide psychosocial care 
for children and adults with disorders of sex development. BMJ paediatrics open 1, e000132, 
doi:10.1136/bmjpo-2017-000132 (2017). 
26 Sanders, C. et al. Involving Individuals with Disorders of Sex Development and Their Parents 
in Exploring New Models of Shared Learning: Proceedings from a DSDnet COST Action 
Workshop. Sexual development : genetics, molecular biology, evolution, endocrinology, 
embryology, and pathology of sex determination and differentiation, doi:10.1159/000490081 
(2018). 
27 Dwyer, A. A., Quinton, R., Morin, D. & Pitteloud, N. Identifying the unmet health needs of 
patients with congenital hypogonadotropic hypogonadism using a web-based needs 
assessment: implications for online interventions and peer-to-peer support. Orphanet J Rare 
Dis 9, 83, doi:10.1186/1750-1172-9-83 (2014). 
28 Ali, S. R. et al. The current landscape of European registries for rare endocrine conditions. 
European journal of endocrinology 180, 89-98, doi:10.1530/EJE-18-0861 (2019). 
29. Flück CE, Meyer-Böni M, Pandey AV, Kempná P, Miller WL, Schoenle EJ, Biason-Lauber A.  
Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed 
for male sexual differentiation. Am J Hum Genet. 2011 Aug 12;89(2):201-18. doi: 
10.1016/j.ajhg.2011.06.009. Epub 2011 Jul 28. Erratum in: Am J Hum Genet. 2011 Aug 
12;89(2):347.  
 
30. Croft B, Ohnesorg T, Hewitt J, Bowles J, Quinn A, Tan J, Corbin V, Pelosi E, van den 
Bergen J, Sreenivasan R, Knarston I, Robevska G, Vu DC, Hutson J, Harley V, Ayers 
K, Koopman P, Sinclair A. Human sex reversal is caused by duplication or deletion 
of core enhancers upstream of SOX9.Nat Commun. 2018 Dec 14;9(1):5319. doi: 
10.1038/s41467-018-07784-9. 
 
COST Perspectives  Page 20 
 
31. . Cox K, Bryce J, Jiang J, Rodie M, Sinnott R, Alkhawari M, Arlt W, Audi L, Balsamo A, 
Bertelloni S, Cools M, Darendeliler F, Drop S, Ellaithi M, Guran T, Hiort O, Holterhus 
PM, Hughes I, Krone N, Lisa L, Morel Y, Soder O, Wieacker P, Ahmed SF. Novel 
Associations in Disorders of Sex Development: Findings From the I-DSD Registry. J 
Clin Endocrinol Metab. 2014 Feb;99(2):E348-55 
 
32. . Lucas-Herald, A. et al. The Long-Term Outcome of Boys With Partial Androgen 
Insensitivity Syndrome and a Mutation in the Androgen Receptor Gene. J Clin 
Endocrinol Metab 101, 3959-3967, doi:10.1210/jc.2016-1372 (2016) 
 
33.  Schweizer, K., Brunner, F., Gedrose, B., Handford, C. & Richter-Appelt, H. Coping With 
Diverse Sex Development: Treatment Experiences and Psychosocial Support During 
Childhood and Adolescence and Adult Well-Being. J Pediatr Psychol, 
doi:10.1093/jpepsy/jsw058 (2016) 
 
34. 34. Ahmed, S. F. et al. Society for Endocrinology UK guidance on the initial evaluation of an 
infant or an adolescent with a suspected disorder of sex development (Revised 2015). Clin 
Endocrinol (Oxf) 84, 771-788, doi:10.1111/cen.12857 (2016). 
 
35. Eggers, S. et al. Disorders of sex development: insights from targeted gene sequencing of a 
large international patient cohort. Genome Biol 17, 243, doi:10.1186/s13059-016-1105-y 
(2016) 
 
36. Ridder, J. D. et al. SDgeneMatch, A New Tool to Aid the Identification of the Genetic 
Causes of DSD. ESPE Abstracts. 89 P-P1-216 (2018) 
 
37. Minto CL, Liao LM, Woodhouse CR, Ransley PG, Creighton SM. The effect of clitoral surgery 
on sexual outcome in individuals who have intersex conditions with ambiguous genitalia: a 
cross-sectional study. Lancet. 2003;361(9365):1252-7. 
 
38. Frisen L, Nordenstrom A, Falhammar H, Filipsson H, Holmdahl G, Janson PO, et al. Gender 
role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal 
hyperplasia due to CYP21A2 deficiency. J Clin Endocrinol Metab. 2009;94(9):3432-9. 
 
39. van der Zwan YG, Janssen EH, Callens N, Wolffenbuttel KP, Cohen-Kettenis PT, van den Berg 
M, et al. Severity of virilization is associated with cosmetic appearance and sexual function in 
women with congenital adrenal hyperplasia: a cross-sectional study. J Sex Med. 
2013;10(3):866-75 
 
40. Callens N, Van Kuyk M, van Kuppenveld JH, Drop SLS, Cohen-Kettenis PT, Dessens AB, et al. 
Recalled and current gender role behavior, gender identity and sexual orientation in adults 
with Disorders/Differences of Sex Development. Horm Behav. 2016;86:8-20. 
 
41. COST Action BM1105, Badiu C, Bonomi M, Borshchevsky I, Cools M, Craen M, Ghervan C, 
Hauschild M, Hershkovitz E, Hrabovszky E, Juul A, Kim SH, Kumanov P, Lecumberri B, Lemos 
MC, Neocleous V, Niedziela M, Djurdjevic SP, Persani L, Phan-Hug F, Pignatelli D, Pitteloud N, 
Popovic V, Quinton R, Skordis N, Smith N, Stefanija MA, Xu C, Young J, Dwyer AA. Developing 
and evaluating rare disease educational materials co-created by expert clinicians and 
patients: the paradigm of congenital hypogonadotropic hypogonadism. Orphanet J Rare Dis. 
2017 Mar 20;12(1):57. doi: 10.1186/s13023-017-0608-2. 
COST Perspectives  Page 21 
 
 
42. Bick D, Jones M, Taylor SL, Taft RJ, Belmont J. Case for genome sequencing in infants and 
children with rare, undiagnosed or genetic diseases. J Med Genet. 2019 Apr 25. pii: 
jmedgenet-2019-106111. doi: 10.1136/jmedgenet-2019-106111 
 
43. Carre GA & Greenfield A.  Characterizing novel pathways in testis determination using mouse 
genetics. Sex. Dev. 8: 199-207 (2014) 
 
44. Carré GA, Siggers P, Xipolita M, Brindle P, Lutz B, Wells S & Greenfield A. (2017) Loss of p300 
and CBP disrupts histone acetylation at the mouse Sry promoter and causes XY gonadal sex 
reversal. Hum. Mol. Genet. 27: 190-198   
 
45. Greenfield, A. Editing mammalian genomes: ethical perspectives. Mamm. Genome 28: 388-
393 (2017) 
 
46. Warr N., Carré GA, Siggers P., Bogani D., Brixey R., Teboul L., Wells S., Sanderson, J. & 
Greenfield A. (2014) Transgenic overexpression of Map3k4 rescues T-associated sex 
reversal (Tas) in mice. Hum. Mol. Genet. 23: 3035-3044 
 
47. Cassatella D, Howard SR, Acierno JS, Xu C, Papadakis GE, Santoni FA, Dwyer AA, Santini S, 
Sykiotis GP, Chambion C, Meylan J, Marino L, Favre L, Li J, Liu X, Zhang J, Bouloux PM, Geyter 
C, Paepe A, Dhillo WS, Ferrara JM, Hauschild M, Lang-Muritano M, Lemke JR, Flück C, 
Nemeth A, Phan-Hug F, Pignatelli D, Popovic V, Pekic S, Quinton R, Szinnai G, l'Allemand D, 
Konrad D, Sharif S, Iyidir ÖT, Stevenson BJ, Yang H, Dunkel L, Pitteloud N. Congenital 
hypogonadotropic hypogonadism and constitutional delay of growth and puberty have 
distinct genetic architectures. Eur J Endocrinol. 2018 Apr;178(4):377-388. doi: 10.1530/EJE-
17-0568. 
 
 
 Box 1: Steps to optimize diagnosis of DSD  
 
We need to be able to differentiate the diagnosis of differences of sex development (DSD) 
conditions, especially of 46,XY DSD, with a stratified approach using both biomarkers and next-
generation sequencing methodology 
• We need to be able to differentiate congenital hypogonadotropic hypogonadism versus 
constitutional delay of growth and puberty 
• We need to identify novel biomarkers for diagnosis and assessment of the utility of refining 
the phenotype to enhance genetic testing 
• We need to further understand the role of environmental factors (such as endocrine 
disruptors, nutrition and exercise) on sex development and delayed puberty or early onset 
central hypogonadism and later outcomes 
• We need to develop personalized counselling of patients using results obtained by next-
generation sequencing technologies 
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• We need to improve genetic counselling (monogenic versus oligogenic forms; estimation of 
variations of undefined significance; extremely variable penetrance and expressivity of 
heterozygous variants) 
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Box 2: Steps to optimize patient management 
 
• We need to increase patient participation in an international registry; investigate and 
overcome the hurdles preventing such participation. 
• The continuous assessment of outcome, patient satisfaction and quality of care is needed.  
o We need to understand the effect of delayed diagnosis and/or inappropriate 
treatment on psychological outcome  
o Patients need targeted psychosocial interventions and enhanced peer-to-peer support 
• The development of clinical benchmarks based on outcomes reported by clinicians, patients 
and parents is required 
• Greater involvement of patients and parents in setting research priorities will aide patient 
management 
• We need to identify specialized care centers  
o Assessment of the quality of care delivered by the specialist centre 
o There is a need for professional education and development of the multi-disciplinary 
care team within the specialist centre 
• A greater awareness of the availability of diagnostic tests in accredited labs is required 
• Adherence to treatment and transition to adult services 
o Interventions to promote adherence and transitional care from pediatric to adult 
services 
• Development of patients’ associations in several countries 
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Box 3: Need for randomized clinical trials (RCT) 
• RCTs for the induction of puberty: need to identify the best treatment and timing of initiating 
treatment both in differences of sex development (DSD) and in congenital hypogonadotropic 
hypogonadism (CHH) 
• Need for multicentre RCTs in patients: 
o without minipuberty and micropenis at birth 
o with delayed puberty (start of treatment at 14–18 years) 
o Gonadotropins versus testosterone on fertility outcome in CHH 
• Long-term studies evaluating: neonatal gonadotropin treatment to optimize fertility; 
gonadotropin treatment during adolescence versus adulthood for fertility optimization; and 
role of prior androgen treatments on fertility outcomes 
• Optimal approach to the induction of fertility in male and female patients 
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Box 4: Needs for acceptance of variant sex development 
• Integration of basic science into DSD-related research to explain the broad range of 
variabilities in sex development and maturation  
• Development of defined prospective outcome studies of medical interventions and their 
omission for better understanding of patient needs in the medical context 
• Guarantee psychosexual assessment and psychological support for patients with DSD and CHH  
• Focusing on gender well-being rather than gender incongruence 
• Defining personalized sex development as a human rights issue and reconciliation of opposing 
views on appropriate management 
• Interactive multidisciplinary and interdisciplinary approaches of natural sciences and 
humanities for better understanding of the socio-cultural context 
• Integration of a broad range of stakeholders into public information and education of both 
professionals as well as the lay public 
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Table 1: Research priorities that are considered to be important by clinicians (Survey by DSDnet 
Ref. 24) 
Area of research Sum Average Least 
important 
Most 
important 
Quality of life 1,005 13.05 0 24 
Gender development 912 11.84 0 10 
Sexual function 855 11.1 1 1 
Genetic aetiology 815 10.58 0 5 
Fertility 812 10.55 1 4 
Communication and understanding 798 10.36 2 9 
Hormone replacement 768 9.97 1 1 
Biochemical investigation 730 9.48 3 6 
Basic mechanisms 710 9.22 1 13 
Cancer 601 7.81 2 2 
Neurocognitive development 531 6.9 6 1 
Epidemiology 514 6.68 10 1 
Cardiovascular health 409 5.31 8 0 
Bone health 406 5.27 9 0 
Model organism research (such as mouse and 
zebrafish) 
309 4.01 17 0 
In vitro stem cell research 297 3.86 16 0 
 
Survey based on 78 respondents (63% response rate). When asked whether “Fundamental 
research is priority in DSD research”, 86% of responders said yes, while 14% said no. When asked 
if “Molecular diagnosis as main goal for fundamental research”, 78% yes, while 22% said no. 
 
